Evidence map›Paper›PMID 40360520›Full record

ArticleNature communications2025

Multicenter target trial emulation to evaluate corticosteroids for sepsis stratified by predicted organ dysfunction trajectory.

Suraj Rajendran, Zhenxing Xu, Weishen Pan, Chengxi Zang, Ilias Siempos, Lisa Torres, Jie Xu, Jiang Bian, Edward J Schenck, Fei Wang

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07511582 (Efficacy, Safety, and Tolerability of Methylprednisolone in Critically Ill Patients With the Hyperinflammatory Phenotype), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07511582 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy, Safety, and Tolerability of Methylprednisolone in Critically Ill Patients With the Hyperinflammatory Phenotype: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Trial

TypeinterventionalSponsorBin DuRan2026 to 2028Enrolled150ConditionsSepsis, Acute Respiratory Distress SyndromeArmsMethylprednisolone (MP), Placebo
3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Suraj RajendranTri-Institutional Computational Biology & Medicine Program, Cornell University, Cornell, NY, USA.ORCID http://orcid.org/0000-0002-8149-0157
Zhenxing XuDivision of Health Informatics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Weishen PanDivision of Health Informatics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Chengxi ZangDivision of Health Informatics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-8244-9551
Ilias SiemposDivision of Pulmonary and Critical Care Medicine, Department of Medicine, New York-Presbyterian Hospital-Weill Cornell Medical Center, Weill Cornell Medicine, New York, NY, USA.
Lisa TorresDivision of Pulmonary and Critical Care Medicine, Department of Medicine, New York-Presbyterian Hospital-Weill Cornell Medical Center, Weill Cornell Medicine, New York, NY, USA.
Jie XuDepartment of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0001-5291-5198
Jiang BianDepartment of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-2238-5429
Edward J SchenckDivision of Pulmonary and Critical Care Medicine, Department of Medicine, New York-Presbyterian Hospital-Weill Cornell Medical Center, Weill Cornell Medicine, New York, NY, USA. ejs9005@med.cornell.edu.ORCID http://orcid.org/0000-0002-7950-5989
Fei WangDivision of Health Informatics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA. few2001@med.cornell.edu.ORCID http://orcid.org/0000-0001-9459-9461

Funding

TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimer’s DiseaseR01AG076448 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng, Li Gan · 2022 to 2026
$4.0M
Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical KnowledgeR01AG076234 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jiang Bian, Fei Wang · 2022 to 2026
$3.8M
Developing Suicide Risk Algorithms for Diverse Clinical Settings using Data FusionR01MH124740 · NIMH · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ASELTINE, ROBERT H, CHEN, KUN · 2020 to 2023
$3.2M
Eligibility criteria design for Alzheimer's trials with real-world data and explainable AIR01AG080991 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jiang Bian, Fei Wang · 2023 to 2026
$3.1M
Disparities of Alzheimer's disease progression in Sexual Minority IndividualsR01AG080624 · NIA · UNIVERSITY OF FLORIDA · PI Jiang Bian, Yi Guo · 2023 to 2026
$3.1M
Identification of Mild Cognitive Impairment using Machine Learning from Language and Behavior MarkersRF1AG072449 · NIA · MICHIGAN STATE UNIVERSITY · PI DODGE, HIROKO HAYAMA, WANG, FEI · 2021 to 2023
$2.6M
Post-Acute Sequelae of SARS-CoV-2 Infection and Subsequent Disease Progression in Individuals with AD/ADRD: Influence of the Social and Environmental Determinants of HealthRF1AG084178 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BIAN, JIANG, HU, HUI · 2023 to 2023
$2.6M
Necroinflammatory Cell Death in SepsisK23HL151876 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHENCK, EDWARD JAMES · 2021 to 2025
$975k
Cellular and Metabolic Dysfunction in Sepsis-Induced Immune ParalysisK23GM151730 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI TORRES, LISA KRISTINA · 2023 to 2025
$588k
NHLBI NIH HHS K23 HL151876NIA NIH HHS R01 AG076234NIA NIH HHS R01 AG076448NIA NIH HHS R01 AG080624NIA NIH HHS R01 AG080991NIA NIH HHS RF1 AG072449NIA NIH HHS RF1 AG084178NIGMS NIH HHS K23 GM151730NIMH NIH HHS R01 MH124740
6 · The paper itself

Abstract

Corticosteroids decrease the duration of organ dysfunction in sepsis and a range of overlapping and complementary infectious critical illnesses, including septic shock, pneumonia and the acute respiratory distress syndrome (ARDS). The risk and benefit of corticosteroids are not fully defined using the construct of organ dysfunction duration. This retrospective multicenter, proof-of-concept study aimed to evaluate the association between usage of corticosteroids and mortality of patients with sepsis, pneumonia and ARDS by emulating a target trial framework stratified by predicted organ dysfunction trajectory. The study employed a two staged machine learning (ML) methodology to first subphenotype based on organ dysfunction trajectory then predict this defined trajectory. Once patients were classified by predicted trajectory we conducted a target trial emulation. Our analysis revealed that the association between corticosteroid use and 28-day mortality varied by predicted trajectory and between cohorts.Our findings suggest that matching treatment strategies to empirically observed pathobiology may offer a more nuanced understanding of corticosteroid utility.

Indexed as

Adrenal Cortex HormonesMultiple Organ FailureRespiratory Distress SyndromeSepsisAgedFemaleHumansMachine LearningMaleMiddle AgedOrgan Dysfunction ScoresPneumoniaRetrospective StudiesShock, SepticAdrenal Cortex Hormones

Identifiers

PMID40360520
PMCPMC12075795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.